Lung penetration and patient adherence considerations in the management of asthma: Role of extra-fine formulations

Journal of Asthma and Allergy

Volumn , Issue 6, 2013, Pages 11-21

  Scichilone, Nicola ^a   Spatafora, Mario ^a   Battaglia, Salvatore ^a   Arrigo, Rita ^a   Benfante, Alida ^a   Bellia, Vincenzo ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Asthma; Device; Inflammation; Quality of life; Small airways

Indexed keywords

BECLOMETASONE DIPROPIONATE; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CORTICOSTEROID; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE PLUS FORMOTEROL FUMARATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; PLACEBO; TECHNETIUM 99M;

AEROSOL; AIRWAY OBSTRUCTION; ALGORITHM; ASTHMA; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE CONTROL; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; PATIENT COMPLIANCE; PRESCRIPTION; RESPIRATORY FUNCTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; TRACHEOBRONCHIAL TREE; TREATMENT FAILURE;

EID: 84874734925     PISSN: 11786965     EISSN: None     Source Type: Journal    
DOI: 10.2147/JAA.S14743     Document Type: Review

References (55)

1. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170(8):836-844.
2. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164(8 Pt 1): 1392-1397.
3. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006;368(9537):744-753.
4. Tulic MK, Christodoulopoulos P, Hamid Q. Small airway inflammation in asthma. Respir Res. 2001;2(6):333-339.
5. Burgel PR. The role of small airways in obstructive airway diseases. Eur Respir Rev. 2011;20(119):23-33.
6. Contoli M, Bousquet J, Fabbri LM, et al The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy. 2010;65(2):141-151.
7. Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol. 1997;100(1):44-51.
8. Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Respir J. 1997;10(2):292-300.
9. Wagner EM, Bleecker ER, Permutt S, Liu MC. Direct assessment of small airways reactivity in human subjects. Am J Respir Crit Care Med. 1998;157(2):447-452.
10. Balzar S, Wenzel SE, Chu HW. Transbronchial biopsy as a tool to evaluate small airways in asthma. Eur Respir J. 2002;20(2):254-259.
11. Ueda T, Niimi A, Matsumoto H, et al. Role of small airways in asthma: investigation using high-resolution computed tomography. J Allergy Clin Immunol. 2006;118(5):1019-1025.
12. Dolhnikoff M, da Silva LF, de Araujo BB, et al. The outer wall of small airways is a major site of remodeling in fatal asthma. J Allergy Clin Immunol. 2009;123(5):1090-1097.
13. The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003;22(3):470-477.
14. Sorkness RL, Bleecker ER, Busse WW, et al; National Heart, Lung, and Blood Institute Severe Asthma Research Program. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol. 2008;104(2): 394-403.
15. Scichilone N, Morici G, Zangla D, et al. Effects of exercise training on airway closure in asthmatics. J Appl Physiol. 2012;113(5): 714-718.
16. Brown RH, Scichilone N, Mudge B, Diemer FB, Permutt S, Togias A. High-resolution computed tomographic evaluation of airway distensibility and the effects of lung inflation on airway caliber in healthy subjects and individuals with asthma. Am J Respir Crit Care Med. 2001;163(4): 994-1001.
17. Fredberg JJ, Jones KA, Nathan M, et al. Friction in airway smooth muscle: mechanism, latch, and implications in asthma. J Appl Physiol. 1996;81(6):2703-2712.
18. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005;172(12):1497-1504.
19. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J. 2002;19(2): 246-251.
20. Ganderton D, Lewis D, Davies R, Meakin B, Brambilla G, Church T. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med. 2002;96 Suppl D:S3-S8.
21. Lewis DA, Ganderton D, Meakin BJ, Brambilla G. Modulite: a simple solution to a difficult problem. Respiration. 2005;72 Suppl 1:3-5.
22. Chapman KR, Love L, Brubaker H. A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects. Chest. 1993;104(5):1332-1337.
23. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. EDICI. Respir Med. 2000;94(5):496-500.
24. Scichilone N, Contoli M, Paleari D, et al. Assessing and accessing the small airways; implications for asthma management. Pulm Pharmacol Ther. October 13, 2012. [Epub ahead of print.]
25. Korn S, Buhl R. Efficacy of a fixed combination of ciclesonide and formoterol: the EXCITED-study. Respir Med 2012;106(1):57-67.
26. Papi A. Inhaled BDP/formoterol extra-fine combination. Evidence and future perspectives. Pneumologie. 2009;63 Suppl 2:S102-S106. German.
27. Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet. 2000;356(9229):556-561.
28. Hauber H, Taha R, Bergeron C, Migounov V, Hamid Q, Olivenstein R. Effects of hydrofluoroalkane and dry powder-formulated corticosteroids on sputum inflammatory markers in asthmatic patients. Can Respir J. 2006;13(2):73-78.
29. Barnes N, Price D, Colice G, et al. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs large-particle chlorofluorocarbon-beclometasone: a real-world observational study. Clin Exp Allergy. 2011;41(11):1521-1532.
30. Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod FB, Bousquet J. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med. 2009;103(1): 41-49.
31. Papi A, Paggiaro P, Nicolini G, Vignola AM, Fabbri LM. Beclomethasone/ formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy. 2007;62(10):1182-1188.
32. Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J. 2007;29(4):682-689.
33. Papi A, Nicolini G, Crimi N, et al. Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial. Respir Res. 2012;13:54.
34. Scichilone N, Battaglia S, Sorino C, et al. Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma. Allergy. 2010;65(7):897-902.
35. Goldin JG, Tashkin DP, Kleerup EC, et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol. 1999;104(6):S258-S267.
36. Cohen J, Douma WR, ten Hacken NH, Vonk JM, Oudkerk M, Postma DS. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J. 2008;31(6):1213-1220.
37. Hozawa S, Terada M, Hozawa M. Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma. Pulm Pharmacol Ther. 2011;24(5):571-576.
38. Leach CL, Kuehl PJ, Chand R, Ketai L, Norenberg JP, McDonald JD. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol. 2012;108(3): 195-200.
39. De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/ formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23(3):137-148.
40. Fabbri LM, Nicolini G, Olivieri D, Papi A. Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives. Expert Opin Pharmacother. 2008;9(3):479-490.
41. Tarsin WY, Pearson SB, Assi KH, Chrystyn H. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int J Pharm. 2006;316(1-2):131-137.
42. Nagel MW, Wiersema KJ, Bates SL, Mitchell JP. Performance of large- and small-volume valved holding chambers with a new combination long-term bronchodilator/anti-inflammatory formulation delivered by pressurized metered dose inhaler. J Aerosol Med. 2002;15(4):427-433.
43. Mariotti F, Sergio F, Acerbi D, Meyer T, Herpich C. Lung deposition of the extra-fine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI in healthy subjects, asthmatic and COPD patients. Presented at the European Respiratory Society 21st Annual Congress, Amsterdam, The Netherlands, September 24-28, 2011.
44. Juniper EF, Price DB, Stampone PA, Creemers JP, Mol SJ, Fireman P. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extra-fine beclomethasone dipropionate. Chest. 2002;121(6): 1824-1832.
45. Muller V, Galffy G, Eszes N, et al. Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extra-fine formulation. BMC Pulm Med. 2011; 11:40.
46. Allegra L, Cremonesi G, Girbino G, et al. Real-life prospective study on asthma control in Italy: cross-sectional phase results. Respir Med. 2012;106(2):205-214.
47. Brusselle G, Peche R, Van den Brande P, Verhulst A, Hollanders W, Bruhwyler J. Real-life effectiveness of extra-fine beclometasone dipropionate/formoterol in adults with persistent asthma according to smoking status. Respir Med. 2012;106(6):811-819.
48. Takeda T, Oga T, Niimi A, et al. Relationship between small airway function and health status, dyspnea and disease control in asthma. Respiration. 2010;80(2):120-126.
49. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
50. Rubin BK. Inhaled corticosteroids: devices and deposition. Paediatr Respir Rev. 2004;5 Suppl A:S103-S106.
51. Rand CS. Adherence to asthma therapy in the preschool child. Allergy. 2002;57 Suppl 74:48-57.
52. Bender B, Zhang L. Negative affect, medication adherence, and asthma control in children. J Allergy Clin Immunol. 2008;122(3): 490-495.
53. Jentzsch NS, Camargos PA, Colosimo EA, Bousquet J. Monitoring adherence to beclomethasone in asthmatic children and adolescents through four different methods. Allergy. 2009;64(10):1458-1462.
54. Graves MM, Adams CD, Portnoy JM. Adherence in young children with asthma. Curr Opin Allergy Clin Immunol. 2006;6(2):124-127.
55. Bender BG. Depression symptoms and substance abuse in adolescents with asthma. Ann Allergy Asthma Immunol. 2007;99(4):319-324.